Approval marks first new class of treatment in decades and the first muscarinic agonist
Low rates of treatment observed, with only 26 percent receiving minimally adequate mental health treatment
Direct causal effect of childhood BMI on schizophrenia seen in Mendelian randomization analyses, independent of adulthood BMI
AA genotype linked to reduced severity, but not occurrence, of TD; no association seen for rs210133 with TD occurrence, severity
Serious complications are rare, with confusion and cognitive side effects most common
Improvements seen in cognition, cholesterol, blood sugar, and C-reactive protein
Association between schizophrenia and cardiovascular disease events more pronounced in women than men
However, neurocognitive declines are seen in others, which is tied to other poor outcomes
Significant improvements seen at eight months for positive symptoms and hallucinations, delusions